Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy (vol 8, 586, 2017)

被引：0
|
作者：
Guerzoni, Simona [1 ]
Pellesi, Lanfranco [1 ]
Baraldi, Carlo [1 ]
Cainazzo, Michela Maria [1 ]
Negro, Andrea [2 ]
Martelletti, Paolo [2 ]
Pini, Luigi Alberto [1 ,3 ]
机构：
[1] Univ Modena & Reggio Emilia, Policlin Hosp, Dept Diagnost Med Clin & Publ Hlth, Headache & Drug Abuse Res Ctr, Modena, Italy
[2] Sapienza Univ, St Andrea Hosp, Dept Clin & Mol Med, Reg Referral Headache Ctr, Rome, Italy
[3] Univ Modena & Reggio Emilia, Ctr Neurosci & Neurotechnol, Dept Biomed Metab & Neural Sci, Modena, Italy
来源：
FRONTIERS IN NEUROLOGY | 2018年 / 9卷
关键词：
chronic migraine; OnabotulinumtoxinA; long-term treatment; quality of life; tolerance; headache; medication overuse headache;
D O I：
10.3389/fneur.2018.00641
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：3
相关论文
共 35 条
  • [31] Long-term efficacy of tenofovir alafenamide in HBeAg-positive and -negative chronic hepatitis B patients treated for up to 8 years in 2 phase 3 studies
    Buti, Maria
    Agarwal, Kosh
    Chan, Henry Ly
    Seto, Wai-Kay
    Lim, Young-Suk
    Brunetto, Maurizia
    Chuang, Wan-Long
    Janssen, Harry
    Fung, Scott
    Izumi, Namiki
    Jablkowski, Maciej
    Abramov, Frida
    Wang, Hongyuan
    Yee, Leland
    Mateo, Roberto
    Flaherty, John F.
    Pan, Calvin
    Shalimar
    Marcellin, Patrick
    Gane, Edward J.
    JOURNAL OF HEPATOLOGY, 2023, 78 : S57 - S57
  • [32] LONG-TERM EFFICACY AND SAFETY OF FREMANEZUMAB IN PATIENTS WITH EPISODIC AND CHRONIC MIGRAINE WHO HAD INADEQUATE RESPONSE TO 2-4 PRIOR MIGRAINE PREVENTIVE MEDICATION CLASSES: OPEN-LABEL EXTENSION OF THE PHASE 3B FOCUS STUDY
    Ashina, Messoud
    Cohen, Joshua M.
    Galic, Maja
    Campos, Verena Ramirez
    Du, Evelyn
    Ning, Xiaoping
    Spierings, Egilius L. H.
    Diener, Hans-Christoph
    CEPHALALGIA, 2020, 40 : 76 - 77
  • [33] Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study (vol 8, e002012, 2022)
    Fleischmann, R.
    Mysler, E.
    Bessette, L.
    RMD OPEN, 2023, 9 (02):
  • [34] Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment. (vol 111, pg 1039, 2008)
    Gambacorti-Passerini, Carlo
    BLOOD, 2008, 112 (02) : 452 - 452
  • [35] Adult Patients with Hemophilia B and with a History of Chronic HCV/HBV Infection Receiving Liver-Directed Gene Therapy Demonstrated Long-Term Bleeding Protection and Sustained FIX Activity: Efficacy and Safety Results from the HOPE-B Trial 3 Years after Administration of a Single Dose of Etranacogene Dezaparvovec
    von Drygalski, Annette
    O'Connell, Niamh
    Verhamme, Peter
    Meijer, Karina
    van der Valk, Paul
    Kazmi, Rashid Saeed
    Raheja, Priyanka
    Galante, Nicholas
    LeQuellec, Sandra
    Church, Rachel
    Lucas, Samantha
    Castaman, Giancarlo
    Monahan, Paul
    BLOOD, 2023, 142
1234